SCHEMBL3847770

SCHEMBL3847770

Cc1cc(C=O)c(C)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
GRIA1 P42261 1/20 0.45
GRIA2 P42262 1/20 0.45
GRIA3 P42263 1/20 0.45
GRIA4 P48058 1/20 0.45
PRKDC P78527 1/20 0.42
TSHR P16473 2/20 0.39
ERN1 O75460 5/20 0.39
LMNA P02545 2/20 0.38
BCHE P06276 1/20 0.34
CES1 P23141 1/20 0.34
KCNJ1 P48048 1/20 0.34
NPC1 O15118 1/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29447325 1.00 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3
SCHEMBL548760 0.91 GRIA1 (0.45) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3
SCHEMBL2884919 0.84 GRIA1 (0.56) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3
SCHEMBL10018128 0.83 PRKDC (0.54) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3
SCHEMBL15920680 0.82 KDM1A (0.43) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3
SCHEMBL21822946 0.80 ERN1 (0.48) ALDH1A1PRKDCTSHRERN1LMNA
SCHEMBL850513 0.80 PRKDC (0.38) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3
SCHEMBL29979076 0.80 TDP1 (0.42) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3
SCHEMBL31028601 0.80 PRKDC (0.38) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3
SCHEMBL22660158 0.80 ERN1 (0.41) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022094-A1 Compounds for the Treatment of Neurodegenerative Diseases CELGENE CORPORATION (US) 2026-01-22 US disclosed
WO-2024019957-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORPORATION (US) 2024-01-25 WO disclosed
WO-2024019957-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORPORATION (US) 2024-01-25 WO disclosed
US-20230331675-A1 AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) 2023-10-19 US disclosed
US-20230331675-A1 AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) 2023-10-19 US disclosed
EP-4212511-A1 AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) 2023-07-19 EP disclosed
WO-2022052926-A1 AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF 广州再极医药科技有限公司 2022-03-17 WO disclosed
US-20210386721-A1 SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2021-12-16 US disclosed
CN-112566905-A Substituted phenyl propenyl pyridine derivatives, preparation method and medical application thereof 上海海雁医药科技有限公司 2021-03-26 CN disclosed
WO-2020228649-A1 SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 上海海雁医药科技有限公司 2020-11-19 WO disclosed
WO-2014094357-A1 HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS ABBVIE INC. (US) 2014-06-26 WO disclosed
US-8525131-B2 Phosphorescent organic compounds THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2013-09-03 US disclosed
US-20120248337-A1 PHOSPHORESCENT ORGANIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-10-04 US disclosed
EP-1969651-B1 SENSITIZING COMPLEXES, THEIR METHOD OF PRODUCTION, HYBRID INORGANIC/ ORGANIC SEMICONDUCTOR MATERIAL COMPRISING THEM, AND PHOTOVOLTAIC CELL COMPRISING THIS MATERIAL COMMISSARIAT ENERGIE ATOMIQUE (FR) 2009-09-16 EP disclosed
US-20080276985-A1 Sensitizing Complexes, Process For The Preparation Thereof, Semiconductive Inorganic/Organic Hybrid Material Comprising Them, And Photovoltaic Cell Comprising Said Material COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2008-11-13 US disclosed
EP-1969651-A1 SENSITIZING COMPLEXES, THEIR METHOD OF PRODUCTION, HYBRID INORGANIC/ ORGANIC SEMICONDUCTOR MATERIAL COMPRISING THEM, AND PHOTOVOLTAIC CELL COMPRISING THIS MATERIAL Commissariat à l'Energie Atomique (FR) 2008-09-17 EP disclosed
US-20070299114-A1 Biaryl Derivatives SHIONOGI & CO., LTD. (JP) 2007-12-27 US disclosed
US-20070299114-A1 Biaryl Derivatives SHIONOGI & CO., LTD. (JP) 2007-12-27 US disclosed
WO-2007071792-A1 SENSITIZING COMPLEXES, THEIR METHOD OF PRODUCTION, HYBRID INORGANIC/ ORGANIC SEMICONDUCTOR MATERIAL COMPRISING THEM, AND PHOTOVOLTAIC CELL COMPRISING THIS MATERIAL COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2007-06-28 WO disclosed
EP-1798224-A1 BIARYL DERIVATIVE Shionogi Co., Ltd. (JP) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299114-A1 Biaryl Derivatives CBR3, NR1H4, CBR1 ALDH1A1 2267/4885SMN1; SMN2 3914/4885GRIA1 283/4885
US-20120248337-A1 PHOSPHORESCENT ORGANIC COMPOUNDS PAICS, PPIP5K2, PPA1 ALDH1A1 2605/4885SMN1; SMN2 2370/4885GRIA1 3170/4885
US-20210386721-A1 SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS PDCD1, CD274, PDCD1LG2 ALDH1A1 26/4885SMN1; SMN2 3068/4885GRIA1 1396/4885
US-20260022094-A1 Compounds for the Treatment of Neurodegenerative Diseases S1PR5, CLN6, S1PR1 ALDH1A1 1518/4885SMN1; SMN2 37/4885GRIA1 1071/4885
US-20230331675-A1 AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF PDCD1, CD274, PDCD1LG2 ALDH1A1 243/4885SMN1; SMN2 3728/4885GRIA1 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.